<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884997</url>
  </required_header>
  <id_info>
    <org_study_id>IIT20210021C-R1</org_study_id>
    <nct_id>NCT04884997</nct_id>
  </id_info>
  <brief_title>A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma</brief_title>
  <official_title>An Exploratory Study of PD-1 Antibody(Toripalimab) or Combining With Temozolomide for Injection in the Treatment of Advanced/Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate toripalimab or combining with temozolomide for injection in the treatment&#xD;
      of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm&#xD;
      B receive toripalimab plus temozolomide&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2021</start_date>
  <completion_date type="Anticipated">September 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>8 weeks</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>8 weeks</time_frame>
    <description>Disease contral rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year PFS</measure>
    <time_frame>1 year after treatment initiation</time_frame>
    <description>progression free survival at 1 year (1year PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month PFS</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>progression free survival at 6 months (6-month PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year OS</measure>
    <time_frame>1 year after treatment initiation</time_frame>
    <description>overall survival at 1 year (1 year OS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year OS</measure>
    <time_frame>2 year after treatment initiation</time_frame>
    <description>overall survival at 2 years (2 year OS) rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>toripalimab 3mg/kg, Q2w;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toripalimab</intervention_name>
    <description>toripalimab 3mg/kg, Q2w;</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>triprizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide Injection</intervention_name>
    <description>Temozolomide 150mg/m2,d1-5,Q4w</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Temoda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  •Confirmed pathologic or cytologic diagnosis of advanced/metastatic malignant&#xD;
             melanomawithout BRAF V600E mutation&#xD;
&#xD;
               -  ECOG PS 0-1;&#xD;
&#xD;
               -  Age :18 ~75 years old;&#xD;
&#xD;
               -  There were measurable lesions according to RECIST 1.1 and the lesions that had&#xD;
                  been irradiated showed definite progression after radiotherapy and the lesion was&#xD;
                  considered measurable only if it was not the only lesion&#xD;
&#xD;
               -  Proper function of the cardiovascular system, liver, kidney and bone marrow ;&#xD;
&#xD;
               -  Subject with at most one systemic therapy for advanced/metastatic malignant&#xD;
                  melanoma&#xD;
&#xD;
               -  Survival is expected to exceed 3 months&#xD;
&#xD;
               -  The subjects showing good compliance voluntarily participated in the study and&#xD;
                  signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  •Previously treated with TMZ, PD-1, or PD-L1;&#xD;
&#xD;
               -  Complicated with other malignant tumors;&#xD;
&#xD;
               -  Subjects with central nervous system metastases and/or cancerous&#xD;
                  meningitis;(Unless the subjects are asymptomatic or have been treated , no&#xD;
                  radiographic evidence of new BMs or BMs enlargement is found at least 2 weeks&#xD;
                  after BMs treatment.If the subjects have active or new untreated asymptomatic&#xD;
                  central nervous system (CNS) metastases found on imaging during the screening&#xD;
                  phase,they must receive radiotherapy&#xD;
&#xD;
               -  Uncontrolled pleural effusion ,pericardial effusion or ascites requiring repeated&#xD;
                  drainage&#xD;
&#xD;
               -  Received major surgical treatment or significant traumatic injury within Random&#xD;
                  28 days prior&#xD;
&#xD;
               -  Severe arterial/venous thrombosis events，Such as cerebrovascular accident&#xD;
                  (including temporary ischemic attack) ,deep vein thrombosis and pulmonary&#xD;
                  embolismwithin Random 6 months prior&#xD;
&#xD;
               -  Subjects with a history of psychotropic substance abuse and being unable to get&#xD;
                  rid of it or with mental disorders&#xD;
&#xD;
               -  Subjects with any severe and/or uncontrolled disease,including :&#xD;
&#xD;
                    1. Subjects with poor blood pressure control (systolic≥ 150 mmHg or diastolic&#xD;
                       ≤100mmHg)&#xD;
&#xD;
                    2. Subjects with myocardial ischemia or myocardial infarction or arrhythmia&#xD;
                       above grade I (including male QTC ≥450ms(male) and female QTC ≥470ms) And&#xD;
                       ≥grade 2 congestive heart failure (New York Heart Association (NYHA))&#xD;
&#xD;
                    3. Active or uncontrolled severe infection (≥CTC AE grade 2 infection)&#xD;
&#xD;
                    4. liver cirrhosis,active hepatitis*;*active hepatitis(Hepatitis B reference:&#xD;
                       HBsAg positive, and HBV DNA test value exceeds the normal valueHepatitis C&#xD;
                       reference: HCV antibody positive, and HCV virus titer detection value&#xD;
                       exceeds the upper limit of normal value&#xD;
&#xD;
                    5. HIV infected&#xD;
&#xD;
                    6. Poor diabetes control (fasting blood glucose (FBG) &gt; 10mmol/L)&#xD;
&#xD;
                    7. urine protein≥++,andConfirmated 24-hour urinary protein quantification&gt;1.0 g&#xD;
&#xD;
                    8. Subjects received a preventive vaccineor attenuated vaccine within 4 weeks&#xD;
&#xD;
                    9. prior to first administration&#xD;
&#xD;
                   10. Participated in other clinical trials within 4 weeks&#xD;
&#xD;
                   11. Active autoimmune disease（Such as the following, but not limited to:&#xD;
                       autoimmune hepatitis interstitial pneumonia enteritis vasculitis,&#xD;
                       nephritis。Subjects with asthma requiring bronchodilators for medical&#xD;
                       intervention were not included） requiring systemic treatment（Such as the use&#xD;
                       of palliative drugs, corticosteroids, or immunosuppressants） occurred within&#xD;
                       2 years prior to initial administration.Alternative therapy(Examples include&#xD;
                       thyroxine, insulin, or physiological corticosteroids for adrenal or&#xD;
                       pituitary insufficiency) is not considered systemic therapy&#xD;
&#xD;
                   12. Other conditions that investigators consider the patients are not suitable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulong Zheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Zheng, PhD</last_name>
    <phone>13588166206</phone>
    <email>drzhengyu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Xiao, PhD</last_name>
    <phone>13588166206</phone>
    <email>drzhengyu@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medical Onocology, First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHENG XIAO, MD</last_name>
      <phone>87235896</phone>
      <email>21218159@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yulong Zheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>malignant melanoma</keyword>
  <keyword>PD-1 antibody</keyword>
  <keyword>temozolomide for injection</keyword>
  <keyword>toripalimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

